05123cam a2200469 i 4500 12925 12925 OSt 20230325152454.0 180316s2018 nyu b 001 0 eng 9781509868087 AEF pcc n-us--- 23rd ed. 338.7/681761 CAR Carreyrou, John, author. 2805 Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou. 2nd ed. London: Picador, 2019 New York : Alfred A. Knopf, 2018. x, 339 pages ; 25 cm text txt rdacontent unmediated n rdamedia volume nc rdacarrier Includes bibliographical (pages 305-324) and index. "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- Provided by publisher. "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- Provided by publisher. Theranos (Firm) History. 2806 Hematologic equipment industry United States. 2807 Fraud United States. 2808 BUSINESS & ECONOMICS / Entrepreneurship. bisacsh 2809 BUSINESS & ECONOMICS / Finance. bisacsh 2810 TECHNOLOGY & ENGINEERING / Biomedical. bisacsh 2811 ddc Book 0 0 ddc 0 0 AEF AEF 2023-04-11 20 374.25 8356 2023-04-11 499.00 2023-04-11 Book